Laurion Capital Management LP Ultragenyx Pharmaceutical Inc. Transaction History

Laurion Capital Management LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$43.02 - $53.69 $2.93 Million - $3.65 Million	68,000 New	68,000 $3.17 Million
Q3 2021 Nov 15, 2021	SELL	$77.92 - $102.4 $227,370 - $298,803	-2,918 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$92.19 - $115.71 $269,010 - $337,641	2,918 New	2,918 $278,000
Q3 2020 Nov 13, 2020	SELL	$72.98 - $90.0 $499,767 - $616,320	-6,848 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$46.91 - $78.22 $321,239 - $535,650	6,848 New	6,848 $536,000
Q1 2020 May 14, 2020	SELL	$33.8 - $62.9 $592,007 - $1.1 Million	-17,515 Closed	0 $0
Q4 2019 Feb 13, 2020	SELL	$36.08 - $45.83 $349,434 - $443,863	-9,685 Reduced 35.61%	17,515 $748,000
Q3 2019 Nov 13, 2019	BUY	$42.5 - $63.11 $1.16 Million - $1.72 Million	27,200 New	27,200 $1.16 Million
Q2 2019 Aug 13, 2019	SELL	$54.93 - $74.36 $1.09 Million - $1.47 Million	-19,823 Closed	0 $0
Q1 2019 May 08, 2019	BUY	$39.87 - $69.36 $790,343 - $1.37 Million	19,823 New	19,823 $1.38 Million

325

85.5M

520K

406K

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $3.14B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

Get notified when there are updates to the investment portfolio of Laurion Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Laurion Capital Management LP with notifications on news.